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A B S T R A C T
Background: The VALidation of HPV GENoyping Tests (VALGENT) is an international initiative designed to
validate HPV assays with genotyping capability. The VALGENT4 protocol differs from previous VALGENT in-
stallments as the sample collection medium is SurePath, and exclusively includes samples from women ≥30
years of age which is concordant with the majority of HPV primary screening guidelines. Here we present the
protocol for the fourth installment of the VALGENT framework.
Objectives: In VALGENT4 11 HPV assays will be evaluated using two comparator assays based on PCR with the
GP5+/6+ primers.
Study design: Overall, the VALGENT4 panel consists of 1,297 routine samples comprised of 998 unselected,
consecutive samples, of which 51 samples had abnormal cytology with 13 women diagnosed with ≥CIN2, and
299 consecutive samples enriched for≥ASCUS cytology (100 ASCUS, 100 LSIL, 99 HSIL) with 106≥CIN2 upon
follow up. Manipulated and DNA extracted panel samples were characterized with respect to human beta globin
(HBB) and overall DNA content and composition to quality assess the panel prior to distribution to the colla-
borating sites.
Result: The relative cellularity (mean CT value of HBB from the Onclarity assay) on the 1,297 LBC samples
(CT=24.8) was compared with 293 un-manipulated routine cytology screening samples (CT=23.8).
Furthermore, the DNA extracted panel samples was characterized using the Exome iPLEX pro assay, which
reports amplifiable copies on individual samples as well as copies of five different base pair lengths. Here the
data showed a slightly lower number of amplifiable DNA copies (ratio: 0.7, p=<0.01)) in the VALGENT4 panel
samples compared to routine extracted cervical DNA samples
Conclusion: The present manuscript details the manipulation, processing and quality assessment of samples used
in VALGENT-4. This methodological document may be of value for future international projects of HPV test
validation.
1. Background
Practically all cervical cancers are derived from an Human pa-
pillomavirus (HPV) infection [1–3] and the causal relation is firmly
established between the development of cervical cancer and at least
12HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and
HPV59, all group 1 carcinogens as classified by IARC) [1,2]. Evidence
on the clinical value of HPV testing for triage of borderline cervical
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cytology and test of cure in women who have been treated for pre-
invasive cervical lesions is today widely accepted [4–6]. Additionally,
randomized controlled trials have provided evidence for the use of
HPV-based screening over cytology as a superior and highly re-
producible screening modality to prevent both invasive squamous and
adeno-carcinomas [5,7]. As a result, primary HPV-based cervical
screening is being implemented in several countries globally, sub-
stituting conventional and liquid based cytology (LBC) as the standard
of care. Together, this has created a rapidly expanding market for
molecular HPV tests, and more than 200 different HPV assays are now
commercially available [8]. As primary HPV based screening becomes
the standard of care, additional focus on evidence of clinical perfor-
mance of HPV assays for use in cervical cancer screening programs is
required.
HPV assays, applicable to cervical screening and disease manage-
ment contexts, have undergone a rapid technical and scientific evolu-
tion over the last decade. The first generation of clinical HPV assays
were developed solely to detect oncogenic HPV genotypes using DNA
PCR or hybridization techniques and mainly reported the test outcome
as either HPV positive or negative, with no individual HPV genotype
information available. Newer generations of commercially available
HPV assays depend upon a wide variety of DNA and RNA detection
techniques and allow for individual reporting of HPV genotypes.
Current HPV genotyping assays can basically be divided into three ca-
tegories (1) Assays with limited genotyping that report separate iden-
tification of HPV16 and HPV18 or HPV18/HPV45, combined with
pooled detection of the remainder of the oncogenic types, (2) Assays
with extended genotyping that report separate identification of ≥5
genotypes combined with one or more bulk detections of the remainder,
and (3) Assays with full genotyping, reporting individual identification
of all carcinogenic HPV genotypes [9].
Studies have assigned different carcinogenic potential, or risk, to
individual HPV genotypes, with HPV16 being the most potent, in par-
ticular for squamous carcinomas of the cervix [10–15], followed by
HPV18 and to some extent HPV45 associated with adenocarcinomas of
the cervix [12,16–18]. Together, up to 70% of all cervical cancers are
caused by HPV16 and HPV18. An additional five HPV genotypes
(HPV31, 33, 45, 52, & 58) add around 19% to the burden of cervical
cancer incidence [16]. Recent study data from long term follow up of a
Danish cervical screening cohort, have shown that persistent infections
with HPV16, HPV18, HPV31 and HPV33 are associated with an in-
creased risk for development of cervical intraepithelial neoplasia grade
3 or worse (≥CIN3) compared to the remaining oncogenic genotypes
[14,19]. The six carcinogenic types HPV35, 39, 51, 56, 59, 68 in con-
trast contribute 8–9% of the cumulative proportion of HPV-induced
cervical cancer [16,20]. Other HPV genotypes incl. HPV66 and 68 are
only rarely involved in cervical carcinogenesis, but both are included in
all oncogenic HPV assays [16]. Finally, genotype distribution among
highly vaccinated cohorts of women have drastically changed affecting
the performance of both cytology screening and HPV genotyping [21].
Taken together, knowledge of the genotype(s) in a screening sample
may add information on the individual woman´s risk of developing
disease [12]. Consequently, HPV technology is progressing from simple
plus/minus outcomes towards revealing more detailed information on
the HPV infection in question. This fact is reflected in a growing
number of national screening guidelines where HPV16/HPV18 geno-
typing is integrated in screening algorithms [5,22,23].
Fulfillment of the “Guidelines for human papillomavirus DNA test re-
quirements for primary cervical cancer screening in women of 30 years and
older” [24], is widely accepted as the methodology by which to validate
HPV assays for screening use [24,25] and several limited or extended
genotyping HPV assays have fulfilled the international guidelines
[25–32]. The international validations are based upon the overall
clinical performance but not with respect to the clinical performance of
detection of individual genotypes per se. Assay specific detection of
individual genotypes has instead been addressed in studies of defined
plasmid based panels with known copy numbers [33,34]. The VALi-
dation of HPV GENoyping Tests (VALGENT) initiative was established
to create a framework for comparison and validation of HPV geno-
typing assays using validated comparator assays, similar to the inter-
national guidelines [24] and using a relevant sample population with
sufficient disease to confirm clinical performance while including pri-
mary screening samples [9]. So far, three installments of VALGENT
protocols have occurred, where a broad variety of HPV assays with both
extended and full genotyping capability have been evaluated [9].
2. Objectives
The fourth installment of the VALGENT framework, the VALGENT4
study, aims to provide high quality comparative data on clinical per-
formance of HPV assays on cervical screening samples. The VALGENT4
protocol differs from previous VALGENT installments as the sample
collection medium is BD SurePath™ (Becton, Dickinson and Company),
targets DNA assays only, and exclusively includes only samples from
women≥30 years of age which is concordant with the majority of HPV
primary screening guidelines. In addition, a high number of assays
previously untested on this LBC collection media will be evaluated.
Moreover, the VALGENT4 protocol is unique in the VALGENT iterations
by proposing a new standard for describing the quality of the sample
panel included.
3. Study design
3.1. Study description
Sample collection, registration, processing and aliquoting was done
at the parent site at the Molecular Pathology Laboratory, Dept.
Pathology, Copenhagen University Hospital, Hvidovre. The VALGENT4
samples will be provided to participating scientific partners anon-
ymized in concordance with Danish Data Protection Agency regula-
tions. Aliquot panels were shipped refrigerated from parent laboratory
to scientific partners.
The VALGENT4 panel was generated using fresh SurePath collected
screening samples from the Danish cervical cancer screening program
which services a well-screened population with a high background risk
of cervical cancer [35]. Moreover, the parent laboratory delivered the
panel in two defined versions; pre-extracted and quality described DNA
for assays requiring DNA as input material (time between collection and
DNA extraction: Mean 28 days, min: 2 days, max: 70 days), and original
LBC material (time between collection and aliquoting for panel: Mean
16 days, min: 2 days, and max: 67 days) to those laboratories where
assays with full, integrated CE-IVD marked work flows were inter-
rogated. The option to have a panel consisting of extracted DNA limits
any variability of various 3rd party DNA extraction platforms on HPV
assay performance. Finally, a novel element entailed characterization of
all included panel samples using a MALDI-TOF assay which measured
the available DNA as well as the relative level of DNA fragmentation in
the individual sample.
In total, eleven different HPV genotyping assays from 8 different
manufacturers will be evaluated in the VALGENT4 study (Table 1),
using GP5+/6+PCR-EIA with genotyping as comparator in line with
previous VALGENT installments.
3.2. Sample collection
The VALGENT4 study was embedded into the routine cytology-
based operations of the Department of Pathology, Copenhagen
University Hospital, Hvidovre, Denmark. This pathology department
receives virtually all cervical cytology screening samples from women
residing in the Danish Capital Region, covering almost a third of the
entire Danish population. Women are invited for screening every three
years at ages 23–49 and every fifth year at ages 50–59. An HPV based
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“check out test” is offered to women 60–64 years of age prior to exiting
the screening program at age 65. The Danish cervical cancer screening
program is free of charge at point of delivery. Samples are collected
predominately by general practitioners or in some cases by gynecolo-
gists. The Combi-brush (Rovers, Oss, Netherlands) is used for collection
of cell material and all cytology samples are collected in SurePath
medium.
Samples from women aged 30–59 years were included in
VALGENT4 study.
The VALGENT4 panel consists of 1297 routine samples collected in
two groups as previously described by the VALGENT framework [9]:
- 998 unselected, consecutive samples, of which 51 samples had ab-
normal cytology (≥atypical squamous cells of undetermined origin,
(ASCUS)). By subsequent histological follow-up, 13 women were
diagnosed with cervical intraepithelial neoplasia 2 or more (≥CIN2)
- 299 consecutive routine samples enriched for≥ASCUS cytology
(100 ASCUS, 100 low-grade squamous intraepithelial lesions (LSIL),
99 high-grade squamous intraepithelial lesions (HSIL)). From this
population, 106 women were presented with≥ CIN2 upon follow
up.
Three samples were discarded after collection due to lack of general
consent after mandatory cross-check in Danish human biological material
in health research projects register (Vævsanvendelsesregisteret).
3.3. Sample processing
SurePath samples nominally contain 10ml of liquid upon arrival in
the laboratory. Currently, the Department of Pathology processes cer-
vical cytology samples using the BD Totalys instrumentation. Here, the
cytology processing uses 8ml of the original sample, which is column
purified for debris and mucus, spun down, pelleted, and re-suspended
in 1ml BD Density Reagent. Of this 1ml medium, 200 μl is used for the
cytology slide procedure. In routine, the remaining 800 μl is auto-
matically added the 2ml of fresh SurePath medium, resulting in a re-
sidual volume of 2.8 ml. By calculation, the final volume of the pelleted
material in the 2.8ml holds a 2.3 times higher concentration of cellular
material than the original material. In order to approximate the cellu-
larity of the original 10ml sample, we developed a reconstitution
protocol utilizing post-cytology pelleted material mixed with residual
original material. The post-cytology pelleted sample was reconstituted
by adding 3.6ml of fresh SurePath medium, resulting in a volume of
6.4 ml (Fig. 1). In addition, the residual, original 2 ml surplus material
from the cytology procedure was added to the 6.4 ml of reconstituted
sample. Consequently, the nominal volume of the reconstituted sample
available for testing in the VALGENT4 protocol was 8.4 ml.
The reconstituted samples were split into aliquots for DNA extrac-
tion and original sample material upon processing of the samples (see
processing time above).
Table 1
HPV genotyping assays evaluated, concurrent material required and scientific partners under the VALGENT4 study protocol.
Valgent-4 included Assays Aliqout Amplicon length Scientific partner
BD Onclarity HPV Assay Original Material 79–137 bp. Hvidovre Hospital, Dept. Pathology, Hvidovre, Denmark
Genomica CLART HPV4 assay DNA 465 bp.
Agena HPV MassArray assay DNA 90–122 bp.
Roche cobas 4800 HPV Test Original Material ∼200 bp Norwegian HPV Reference Lab,
Akershus University Hospital
Norway
Fujirebio INNO-LiPA Genotyping Extra II
test
DNA 65 bp Ghent University Hospital, Ghent, Belgium
SeeGene Anyplex HPV28 detection test
Seegene Anyplex II HPV test
DNA or Original
Material
∼150 bp
∼150 bp
Infection and Cancer Laboratory. Cancer Epidemiology Research Program, Institut
Català d'’OncologiaBarcelona, Spain
Self-screen HPV-Risk assay DNA ∼150 bp Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
Genefirst HPV-MPA Genotyping Test DNA 150 bp. Scottish HPV Reference Lab,
Royal Infirmary of Edinburgh
Scotland
Liferiver Harmony test
Liferiver Venus tes
DNA 100–200 bp.
100–200 bp.
Comparator assays
GP5+/6+EIA Luminex DNA DDL Diagnostic Laboratory, Rijswijk, The Netherlands
GP5+/6+PCR EIA kit HPV GP HR DNA International HPV Reference Center, Karolinska University Hospital, Stockholm, Sweden
Fig. 1. Flowchart.
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3.4. DNA extraction
DNA was extracted under strictly controlled conditions using stan-
dard operating procedure clinically routine DNA extraction protocol at
the parent laboratory based upon the MagNA Pure96 system (Roche
Diagnostics, Pleasanton, CA). In short, 4× 1ml aliquots of recon-
stituted material were transferred to four Eppendorf tubes, spun down
(14,000 rpm, 5min), the supernatant removed, and the pellet re-sus-
pended in a mix of 180 μl phosphate buffered saline (10x conc. pH 7.4,
Pharmacy product) and 20 μl Proteinase K (Recombinant, PCR grade,
Roche Diagnostics). The samples were vortexed and incubated one hour
at 56 °C for Proteinase K digestion. Subsequently, the tubes were in-
cubated for one hour at 90 °C to reverse SurePath formaldehyde in-
duced co-valent cross linking. The entire volume was transferred to the
MagNA Pure 96 system and extracted using the MagNA Pure LC Total
Nucleic Acid Isolation Kit (Roche Diagnostics). The four DNA eluates
were pooled into one tube to a total volume of 400 μl.
3.5. Cytology
Cytology was reported according to the Bethesda 2001 criteria,
using computer assisted reading by BD Focal Point and Slide Wizard
systems. ASCUS cases were triaged (reflex testing) routinely with HPV
testing (BD Onclarity). All abnormal cytology findings were adjudicated
as per standard operating procedures of the parent laboratory by a se-
nior pathologist. Women with LSIL were recommended for repeated
cytology testing after 6 months. Women with inadequate cytology were
recommended for repeated sampling and testing within 3 months.
Women with normal cytology were returned to routine screening ac-
cording to age-specific intervals. The complete screening history of the
women included in VALGENT4 was retrieved from the Danish
Pathology Data Bank (PatoBank). All clinical follow up was managed
according to Danish guidelines, and the outcome of the VALGENT4
HPV testing did not affect clinical follow up recommendations. All HPV
testing performed in the framework of VALGENT4 was blinded to cy-
tology and clinical follow-up.
3.6. Histology
All histology available for disease ascertainment was derived from
the clinical follow-up of women whose samples were included in the
VALGENT4 cohort. The following screening sample outcomes elicit a
recommendation for follow-up with colposcopy and biopsy-taking
under the current Danish guidelines:
• Women, ≥30 years with ASCUS and HPV-positivity upon triage
testing.
• Women with HSIL, atypical squamous cells – cannot exclude HSIL
(ASC-H), atypical glandular cells (AGS) or cytological indications of
carcinoma.
• Women with continued ASCUS and LSIL cytological diagnosis, as
evaluated by the present sample and screening history.
Danish Gynecology Guidelines recommend biopsy taking on all
aceto-white lesions observed, or a random four quadrants biopsy set
where no lesions are visible upon colposcopy. The histological follow-
up for all women included in the VALGENT4 study was retrieved from
the PatoBank.
3.7. Data source for clinical outcomes
The PatoBank follow-up period was on average 19 months (min. 18
months; max 20 months) from collection of the VALGENT4 samples.
The registration of cervical cytology and histology in the PatoBank has
been complete on a national level since 2008.
3.8. Participating scientific partner panel testing
All HPV testing within VALGENT4 was blinded to cytology and
histology outcomes from the parent laboratory as well as the HPV test
results from other scientific partners. All test results were reported to
the Scientific Institute of Public Health, Brussels, where the data are
compiled, and performance calculations are conducted [9]. All HPV
testing was performed according to manufacturer’s specifications. Nine
different participating scientific partners (including the parent site) are
taking part in the VALGENT4 study (Table 1).
3.9. Pre-analytical characterization of LBC material and DNA aliquot panel
samples
3.9.1. Pre-analytical characterization of cellularity of reconstituted original
LBC material
All 1297 panel samples were tested with the BD Onclarity HPV
assay (Onclarity) on the automated Viper Lt platform under the
VALGENT4 protocol. The Onclarity assay harbors an internal Human
Beta globin (HBB) control for assay performance and sample adequacy.
To evaluate the resulting cellularity of the resuspension protocol, mean
HBB Ct values from the 1297 VALGENT4 samples were retrieved from
the Viper Lt and used as a proxy marker for cellularity. As comparator,
mean HBB Ct values of unselected, unannotated routine cervical
screening SurePath samples were used as a reference group for cellu-
larity (designated “Control-1”, N= 293). The Onclarity assay on the
Viper Lt Platform workflow has previously been described in detail
[27,36]. In summary, 0.5 ml original SurePath material is transferred to
a BD CBD medium tube prior to heat treatment for 30min at 120 °C on
the BD pre-warm station. The pre-warmed samples are subsequently
transferred to the fully automated Viper Lt platform and tested with the
Onclarity assay according to manufacturer’s recommendations. Mean
HBB values between the two groups were compared using one-way
ANOVA testing (IBM SPSS ver. 22).
3.9.2. Amplifiable DNA copies and DNA fragmentation evaluation of DNA
extracts
The iPLEX PRO ExomeQC assay (Agena Bioscience, Hamburg) is a
quantitative assay which reports average amplifiable human DNA co-
pies in a sample, in addition to reporting the relative number of am-
plifiable fragments of 100, 200, 300, 400, and 500 base pairs (bp)
lengths. Here, the assay was used as a quality control of the DNA ex-
tracts derived from the reconstituted VALGENT4 panel. As comparator,
DNA from unselected, unannotated, and un-manipulated SurePath
cervical screening samples collected from the routine service were used
as reference (designated “Control-2”, N=184).
The ExomeQC panel harbors 44 Single Nucleotide Polymorphisms
(SNPs), three markers for gender identification and five copy-number
markers in a single multiplexed assay. The assay uses the Matrix
Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry
(MALDI-TOF MS) technology. An initial multiplex PCR amplification
was set up with 2 μl DNA (duration: 2.5 h), followed by a Shrimp
Alkaline Phosphatase (SAP) reaction (dephoshorylize excess
Nucleotides, duration: 50min). This was followed by an iPLEX Pro
single base extension PCR reaction in which a mix of oligonucleotide
extension primers designed to anneal to the amplified DNA fragments,
was added together with an extension enzyme and mass-modified di-
deoxynucleaotide terminators (duration 3.5 h). The extension products
were subsequently desalted with Clean Resin prior to being loaded into
the MassArray Dx Nanodispenser RS1000 (Agena Bioscience,
Hamburg), which transfers the analyte to a spectroCHIP. Here the
sample crystalize with the matrix on the chip, which was then analyzed
on the MassARRAY Dx Analyzer 4 (Agena Bioscience, Hamburg). The
crystals were irradiated by a laser, inducing desorption and ionization.
The MA4 accelerates the samples to a detector that differentiates ge-
netic variants by molecular mass.
J. Bonde et al. Journal of Clinical Virology 108 (2018) 64–71
67
3.9.3. Statistical analysis
The Onclarity assay has a three well set-up with nine HPV genotype
read-outs with internal HBB control included in each well. The Ct-value
of the HBB was calculated as an average of the three HBB Ct values in
each of the three wells for every panel and control sample. The
Onclarity cut-off for all channels is Ct 34.2. For the ExomeQC analysis,
inadequate samples (insufficient number of SNPs detected) and samples
with outlier values above 10,000,000 units were excluded in the re-
sulting analysis. Mean Ct, mean available copy numbers, 95% con-
fidence interval, standard deviations as well as the one-way ANOVA test
used to calculate the statistical difference in cellularity and DNA in-
tegrity parameters between the VALGENT4 panel and Control-1 and 2
samples were calculated using IBM SPSS statistics 22.
4. Results
The overall characteristics of the VALGENT4 study population are
summarized in Table 2. The mean age was 42.8 years for all included
women, and 40.4 and 42.2 years for the unselected, consecutive and
enriched subpopulations, respectively. In the 998 consecutive, un-
selected panel samples, 5.1% (51 samples) had abnormal cytology and
as of March 2018, 1.3% (13 samples) had≥ CIN2 follow-up histology
registered in the Danish National Pathology Registry (PatoBank). The
enriched population of 100 ASCUS, 100 LSIL and 99 HSIL cytology
samples resulted in 106≥ CIN2 histology samples as per register up-
date March 2018. In total, 119≥ CIN2 cases were registered at data
retrieval ≥20 month after baseline.
Comparing the relative cellularity (mean Ct values of HBB control
from the Onclarity assay) on the 1,297 LBC panel samples with data
from 293 separately collected, un-manipulated routine cytology
screening samples (Denominated “Control-1” samples, Table 3A). The
mean Ct value of the VALGENT4 samples (Ct= 24.8) was found to be
on average 1.0 Ct above the mean Ct value of the Control-1 samples
(Ct= 23.8), indicating slightly less cellularity in the panel samples
compared to native samples.
For DNA extracted panel samples, characterization was done using
the Exome iPLEX pro assay, which reports amplifiable copies on in-
dividual samples as well as amplifiable copies at five different base pair
lengths (Table 3B). Here, the data showed statistically difference in the
number of amplifiable DNA copies comparing the VALGENT4 panel to
the Control-2 population (ratio of 0.7, p-value< 0.01). When looking
at the relative proportion of different base pair length fragments, the
statistical difference was only evident at the longest 400 and 500 bp
fragments (Table 3B).
5. Discussion
The VALGENT framework is an international cooperation aimed at
evaluating HPV genotyping tests for clinical use in cervical cancer
screening. Here we present the study protocol for the fourth installment
of the VALGENT framework, presenting data that provides insight into
the underlying quality of the 1,297 VALGENT4 samples. One of the
novel elements in VALGENT4 is the resuspension protocol employed
which attempts to emulate the original cellularity of un-manipulated
screening samples (Fig. 1).
For research use, most cross-sectional studies where HPV tests are
applied rely on stored, residual clinical cytology screening material. In
contrast, most HPV tests are intended to run on recently collected and
un-manipulated original sample material. In addition, for evaluations
where multiple assays are applied to samples, the volume of sample
may be a rate-limiter. Consequently, to reconcile the need for authen-
ticity with the operational requirements of the study, we developed a
Table 2
Overall characteristics of the VALGENT4 study population.
Screening population Enriched populationa Total population
Characteristics N % N % N %
Age
Mean Age in years 42.8 (36.0–49.0) 40.4 (34.0–45.8) 42.2 (36.0–48.0)
30-39 383 38.4% 148 49.8% 531 41.0%
40-49 408 40.9% 111 37.4% 519 40.1%
50-59 207 20.7% 38 12.8% 245 18.9%
30–59 998 100% 297 100% 1,295 100%
Cytology
NILM 947 94.9% 0 0% 947 73.0%
ASCUS 6 0.6% 100 33.3% 106 8.2%
LSIL 21 2.1% 100 33.3% 121 9.3%
HSIL. AGC. ASC-H 24 2.4% 99 33.3% 123 9.5%
Total 998 100% 299 100% 1297 100%
Histology
No histology 911 91.3% 55 18.4% 966 74.6%
Normal 57 5.7% 82 27.4% 139 10.7%
CIN1 17 1.7% 54 18.1% 71 5.5%
CIN2 5 0.5% 34 11.4% 39 3.0%
CIN3 7 0.7% 64 21.4% 71 5.5%
Cancer 1 0.1% 8 2.7% 9 0.7%
All histologies 87 8.7% 242 80.9% 329 25.4%
<CIN2 74 7.4% 136 45.5% 210 16.2%
≥CIN2 13 1.3% 106 35.5% 119 9.2%
a Two women enrolled in Valgent4 each had two samples included; therefore therefor 299 samples from 297 women are included in the enriched cohort.
Table 3A
Quality assurance of the VALGENT4 LBC samples: Mean HBB Ct value as ap-
prox. marker for cellularity.
Group N Mean
HBB Ct
Ratioa St.d 95%
Confidence
Incidence
Min Max P-valueb
Lower Upper
Valgent4 1297 24.8 1.04 1.5 24.7 24.9 20.8 32.3 0.00
Control1 293 23.8 1.00 1.5 23.6 24.0 20.5 32.0
a The Control1 population was used as a reference.
b p-value is calculated using the one-way ANOVA test.
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reconstitution protocol taking into account the changes introduced to
the freshly collected VALGENT4 samples by routine cytology proces-
sing. The aim was to reestablish the residual cytology pelleted material
to an approximate per volume cellularity corresponding to the original
cellularity in un-manipulated clinical samples (Fig. 1). This recon-
stitution protocol was developed with the assistance of Becton, Dick-
inson and Company, the manufacturer of the SurePath medium, by
reverse engineering the concentration and resuspension steps included
in standard SurePath processing of original, fresh samples.
As the mean beta globin Ct value of the VALGENT4 samples
(Ct= 24.8) was found to be 1.0 Ct above the Control-1 samples
(Ct= 23.8), this suggests that the reconstituted panel samples had
slightly lower cellularity than freshly collected, un-manipulated
screening samples. However, in the context of the clinical positive-ne-
gative Onclarity HPV assay cut off (Ct 34.2), the reconstituted panel
samples were fully acceptable as clinically, analytical material for HPV
analysis. In combination with the ratio data from the ExomeQC ana-
lysis, this describes the resulting degree of dilution introduced to the
reconstituted panel samples compared to the original sample cellu-
larity. Moreover, the DNA fragmentation analysis showed that fresh,
un-manipulated samples had more 400 and 500 bp DNA fragments
compared to the reconstituted panel samples. This clear trend down-
wards between reconstituted samples and original samples in Control-2
was however not unexpected as all sorts of manipulation of cells and
DNA leads to some level of deterioration. Whether this has implications
for the analytical and clinical performance of HPV assays is unlikely,
given that all included assays in the VALGENT4 protocol rely on am-
plification of less than 500bp HPV fragments (Table 1).
In conclusion, the two QA/QC methods employed indicate that the
reconstituted samples used for the VALGENT evaluation contain
slightly less analytical material compared to fresh, un-manipulated
screening samples. However, the amount of analytical relevant material
is reassuringly within the operational boundaries of all included
VALGENT4 HPV assays (Table 1).
Besides the reconstitution protocol, VALGENT4 introduced central
organization of DNA extraction for all assays running on this input
material. This was chosen to eliminate any variation introduced at the
level of DNA extraction methodology. Of the 11 assays evaluated in
VALGENT4, only BD Onclarity, Seegene Anyplex HPV28/HPV II HR
and Roche Cobas HPV assays required original SurePath LBC material
as input material for analysis.
Until now, three VALGENT installments have been completed with
several genotyping assays tested. The data from these VALGENT studies
has showed that the VALGENT framework provides a good base for
cross-sectional clinical validation of HPV genotyping assays, by use of
well annotated cervical screening samples collected in various
screening programs around Europe [9]. A common feature of the
VALGENT installments is the use of GP5+/6+PCR-EIA as the com-
parator assay to all other included assays. This brings the VALGENT in
line with the stipulations within the international validation Guidelines
of Meijer et al.
The first VALGENT study, VALGENT-1, included cervical cancer
screening samples provided by the AML laboratory (Antwerp, Belgium)
and included validation of four full genotyping assays [37–39]. The
VALGENT-1 framework included SurePath samples from biobanked
screening samples, and thus not freshly collected samples as included
here. The second VALGENT study, VALGENT-2, used ThinPrep, in-
volved the collection of samples from the Scottish Cervical Screening
Programme via the Scottish HPV Reference laboratory and involved the
evaluation of four assays with genotyping capability [40–43]. VAL-
GENT-3 also included ThinPrep collected cervical cancer screening
samples, this time from the Laboratory for Molecular Microbiology,
Faculty of Medicine, University of Ljubljana, Slovenia [44] and eval-
uated 10 different HPV assays with different degrees of genotyping
capability. VALGENT-1 [37–39] and VALGENT-2 [40–43] have both
provided several peer-reviewed papers and publications from VAL-
GENT-3 are underway [32,44]. Formal clinical validation of HPV assays
for use in screening has primarily been undertaken on ThinPrep col-
lected samples [24,26,28,30,41,45,46], with only one assay to date, the
BD Onclarity, being validated on both ThinPrep [26] and SurePath
collected samples [27]. Following this, it will be interesting to see how
the HPV genotyping assays included in VALGENT4 perform on Sur-
ePath collected screening samples in this large-scale performance
comparison.
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